Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

Video

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.